SARS-CoV-2 B 位导向的新抗原纳米疫苗通过B细胞抗原呈现增强瘤特异性的CD4/CD8 T细胞免疫力
Chengyi Li1, Fang Ke1, Shuai Mao1
1Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States.
ACS nano
|February 13, 2025
概括
新的癌症纳米疫苗引导B细胞呈现抗原,增强CD4/CD8T细胞免疫力,对黑色素瘤,胰腺癌和乳腺癌产生优异的抗癌作用.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 疫苗开发 疫苗开发
背景情况:
- 目前的新抗原癌症疫苗依赖于树突细胞/巨细胞抗原呈现.
- B细胞介导抗原呈现在增强新抗原疫苗疗效方面的作用尚不清楚.
研究的目的:
- 开发和评估SARS-CoV-2 B细胞表位导向的新抗原/mRNA癌症纳米疫苗 (BSARSTNeoAgVax).
- 通过通过B细胞介导抗原呈现来提高瘤特异性CD4和CD8T细胞免疫力来增强抗癌疗效.
主要方法:
- 通过将SARS-CoV-2 B细胞表位与新抗原/mRNA相结合,开发出BSARSTNeoAg疫苗.
- 在黑色素瘤,胰腺癌和乳腺癌的临床前模型中评估了疫苗的疗效.
- 评估了对CD4 T细胞 (毛囊和非毛囊) 和CD8 T细胞反应的影响.
主要成果:
- BSARSTNeoAg疫苗有效地激活了B细胞受体,促进了对CD4T细胞的抗原呈现.
- 纳米疫苗增加了瘤特异性的CD4 T细胞,并增强了B细胞依赖的CD8 T细胞免疫力.
- 与当前的新抗原疫苗相比,在多种癌症模型中显示出更高的抗癌疗效.
结论:
- 以SARS-CoV-2 B表位导向的新抗原纳米疫苗代表了癌症治疗的通用平台.
- 这种方法通过病毒特异性B细胞介导的抗原呈现来增强CD4/CD8 T细胞抗瘤免疫力.
- 开发的纳米疫苗有望改善各种癌症类型的疗效.
相关概念视频
Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Cancer Vaccines
329
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
329
Rous Sarcoma Virus (RSV) and Cancer
4.9K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
4.9K
Immune Response Against Viral Pathogens
731
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
731
Vaccinations
43.8K
Overview
43.8K


